All In Biotech

Drug Trial Radar · NCT05256290

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Mar 31, 2022

Primary completion

Mar 2028

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.

Conditions

  • Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Squamous Lung Cancer
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Lung Cancer
  • NSCLC
  • Advanced Lung Carcinoma
  • Epidermal Growth Factor Receptor C797S
  • Epidermal Growth Factor Receptor G719X
  • EGF-R Positive Non-Small Cell Lung Cancer
  • EGFR-TKI Resistant Mutation

Interventions

  • silevertinib monotherapyDrug

    Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)Time frame: The first treatment 21-day cycle (Cycle 1)
  2. Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)Time frame: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
  3. Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD doseTime frame: Through study completion, approximately 1 year

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • Sibley Memorial Hospital Johns Hopkins Medicine

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic- Jacksonville

    Jacksonville, Florida · Recruiting

  • Miami Cancer Institute - Baptist Health South Florida

    Miami, Florida · Recruiting

  • UHP- University of Hawaii Cancer Center

    Honolulu, Hawaii · Recruiting

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic- Rochester

    Rochester, Minnesota · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • Next Oncology

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center/University of Washington

    Seattle, Washington · Recruiting

  • BC Cancer Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • The Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.